|Bid||49.00 x 1800|
|Ask||49.05 x 1800|
|Day's Range||46.90 - 49.80|
|52 Week Range||16.10 - 49.80|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 24, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||40.40|
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as NovoCure Limited (NASDAQ:NVCR) with a market-capitalization of US$4.36b, rarely draw their attention. However, history shows that overlookedRead More...
Easily the biggest trend in investing has to be healthcare stocks. From rising and aging populations in the developed world to new middle-class consumers gaining access to healthcare for the first time in emerging markets, healthcare demand is only getting bigger by the day. All in all, the combination of the two factors makes the medical device stocks some of best plays in all of healthcare.
Novocure (NVCR), a global oncology company developing a proprietary platform technology called Tumor Treating Fields, and Zai Lab (ZLAB), a Shanghai-based innovative biopharmaceutical company, announced today an exclusive license agreement for Tumor Treating Fields, including the brand name Optune, in Greater China and a global strategic development collaboration. This agreement will enable Novocure to access the Chinese market and is intended to accelerate clinical trial enrollment.
On September 6, NovoCure (NVCR) stock rose 5.3% to reach $45.40 compared to the previous day’s close of $43.10. Also, on September 6, NovoCure hit its 52-week high of $46.73. Its closing price for the day represents ~182% growth from its 52-week low of $16.10 on October 13, 2017.
NEW YORK, NY / ACCESSWIRE / September 6, 2018 / Major U.S. equities were mixed on Wednesday with tech stocks posting worst daily drop since July dragging Nasdaq lower. The Dow Jones Industrial Average ...
Novocure (NVCR) announced final results from its STELLAR phase 2 registration trial in mesothelioma, demonstrating a significant extension in median overall survival among patients treated with Tumor Treating Fields plus standard of care chemotherapy compared to historical control data of patients who received standard of care chemotherapy alone. Malignant pleural mesothelioma patients who received Tumor Treating Fields with pemetrexed and cisplatin or carboplatin experienced median overall survival of 18.2 months (95 percent CI, 12.1-25.8 months) compared to 12.1 months in a historical control.
This year, more than 14,000 people in the U.S. will be diagnosed with the same kind of brain cancer that killed Senator John McCain, glioblastoma multiforme, or GBM.
NEW YORK, NY / ACCESSWIRE / August 24, 2018 / U.S. markets plunged on Thursday following the release of the minutes from the latest Federal Reserve meeting, which called for an interest hike in September. ...
NEW YORK, Aug. 23, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Genesis ...
NovoCure’s (NVCR) net financial expenses increased from $2.18 million in the second quarter of 2017 to $2.86 million in the second quarter. NovoCure’s income tax expenses also increased from $3.46 million in the second quarter of 2017 to $5.56 million in the second quarter.
NovoCure (NVCR) is mainly engaged in developing and bringing tumor treating fields for solid tumors to the market. The company’s first tumor treating fields delivery system, Optune, is targeted to treat adult patients with glioblastoma. Tumor treating fields use electric fields tuned to certain frequencies to disrupt solid tumor cancer cell division.
NovoCure (NVCR) generated revenues of $61.51 million in the second quarter—compared to $38.38 million in the second quarter of 2017. The growth was also driven by NovoCure’s initial launch efforts in Japan. NovoCure incurred a cost of revenues of $19.83 million in the second quarter—compared to $13.15 million in the second quarter of 2017.
Orgenesis (ORGS) is an underfollowed player in the biotech sector, but with growing revenue and high-profile clients and partners. Most recently, a prestigious healthcare institute Great Point Partners invested up to $25 million directly in their subsidiary and is acting as a key advisor for their global business expansion. Fundamentals are looking good at ORGS as revenue climbed 73% in fiscal Q2, over the year-ago period.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Canopy Growth Corp (NYSE: CGC ) stock gained more ...
Novocure (NVCR) and US Oncology Research are collaborating on PANOVA-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine in patients with unresectable locally advanced pancreatic cancer. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die.
Novocure (NVCR) has announced an addition to its board of directors. Jeryl (Jeri) Hilleman, an experienced executive leader, was elected to Novocure’s board in July 2018. “We are extremely pleased to welcome Jeri to our board of directors,” said Bill Doyle, Novocure’s Executive Chairman.
Novocure (NVCR) announced today that the results of its INNOVATE phase 2 pilot trial have been published in Gynecologic Oncology. The INNOVATE trial was a prospective, single-arm study testing the feasibility, safety and preliminary efficacy of Tumor Treating Fields combined with weekly paclitaxel in recurrent ovarian cancer. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die.
NovoCure (NVCR) released its second-quarter results on July 26. In the second quarter, NovoCure continued to see steady growth in patient prescriptions for new glioblastoma diagnosis. NovoCure reported a net loss of $15.51 million in the second quarter—compared to a net loss of $21.17 million in the second quarter of 2017.
Quarterly net revenues of $61.5 million, representing 60 percent growth versus the second quarter 2017 and 18 percent growth versus the first quarter 2018